TAG:
lab executive
2013’s Top Ten Lab Stories Point to Tougher Times
By Robert Michel | From the Volume XX, No. 17 – December 23, 2013 Issue
CEO SUMMARY: For 2013, the big story was money—or, more accurately, less money for providers. This was not limited to clinical labs and pathology groups, but was equally true of hospitals and physicians. In THE DARK REPORT’S annual lookback at the year’s 10…
Georgia Lab Pays Docs For Urine Test Referrals
By Joseph Burns | From the Volume XX, No. 16 – December 2, 2013 Issue
CEO SUMMARY: Physicians could make $400 or more per sample, according to one physician. But under the federal Stark Law, the federal Anti-kickback Law, and under Florida state law, physicians and other healthcare providers are prohibited from referring patients or doing work for kickbacks…
Charting Your Lab’s Course for 2014
By R. Lewis Dark | From the Volume XX, No. 16 – December 2, 2013 Issue
WITHOUT QUESTION, CLINICAL LABS AND PATHOLOGY GROUPS will be confronted with tough challenges during 2014. Across the nation, lab executives and pathologists tell us that it is no longer “business as usual.” What I find most interesting about the feedback pouring into our offices is that the Aff…
November 11, 2013 “Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume XX No. 15 – November 11, 2013 Issue
Who would have guessed that Angelina Jolie would do a multi-million-dollar favor to Myriad Genetics, Inc.? Jolie caused quite a stir earlier this year when she went public with the news that she had done a prophylactic double mastectomy after she had learned the results of her BRCA test for br…
CMS Ready To Hack Away at Cost of Lab Testing
By Robert Michel | From the Volume XX No. 12 – September 9, 2013 Issue
CEO SUMMARY: In July, the federal Centers for Medicare & Medicaid Services (CMS) published three proposed rules which would allow it to act independently of Congress to set prices for clinical laboratory testing and pathology services. Analyses of these proposed rules indicate that th…
Prosecutors Ready to Target Pain Management
By R. Lewis Dark | From the Volume XX No. 11 – August 13, 2013 Issue
OVER THE PAST DECADE, many lab executives and pathologists have become aware of the abusive activities in the field of drugs of abuse testing and pain management testing. The frustration for those who understood the true scale of the fraud and abuse in this sector of healthcare was that no federal or…
Labs Push to Cut Costs As Budgets, Prices Shrink
By Robert Michel | From the Volume XX No. 11 – August 13, 2013 Issue
CEO SUMMARY: Cost-cutting is now the prime directive at progressive labs because nearly every laboratory organization in the United States is under sustained financial pressure. This is due to shrinking budgets for hospital labs and more aggressive price-cutting by private payers. Even Ob…
Feds Nail Doctors for Accepting Bribes from Labs
By R. Lewis Dark | From the Volume XX No. 10 – July 29, 2013 Issue
HALLELUJAH! FOUR DOCTORS IN NEW JERSEY HAVE PLEADED GUILTY to federal criminal charges of accepting bribes from Biodiagnostic Laboratory Services (BLS), the clinical lab company in Parsippany, New Jersey. Can any of you remember the last time that a federal prosecutor pursued crimina…
House Bill Introduced to Address Rate-Setting for Molecular Tests
By Robert Michel | From the Volume XX No. 10 – July 29, 2013 Issue
FEW PATHOLOGISTS OR CLINICAL laboratory directors would argue against revising the current Medicare payment policies for molecular and genetic tests. A bill proposed in Congress would do just that. The process now in use by Medicare Administrative Contractors (MACs) is inefficient and opaque, accord…
Laboratory Offers Early Lessons in Positioning for Success with ACOs
By Joseph Burns | From the Volume XX No. 10 – July 29, 2013 Issue
CEO SUMMARY: Accountable care organizations (ACOs) are already leading the shift from fee-for-service reimbursement to population payment. ACOs are leading healthcare’s evolution to preventive care, wellness, and better management of patients with chronic disease. This evolution will re…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized